Insights From The Reprieve Trial: A Whirlwind Review Of Study Publications And Results

Insights from the REPRIEVE Trial: A Whirlwind Review of Study Publications and Results

UC San Diego AntiViral Research Center

Day 2 at IAS 2023 How the REPRIEVE Trial Findings Could Help Improve Care for People with HIV

Results From the REPRIEVE Trial: Implications for the Clinical Care of Patients with HIV

IAS 2023: The REPRIEVE trial

IAS – the International AIDS Society

Daily statin reduces the risk of cardiovascular disease in people living w/ HIV

The Curbsiders Internal Medicine Podcast

Cardiovascular Disease Prevention in Patients With HIV: The REPRIEVE Trial

The REPRIEVE Trial: Practice Changing or Practice Affirming?

MWAETC: Project ECHO

REPRIEVE Community Forum - September 21, 2023

Day 2 at IAS 2023 REPRIEVE Study and Long-Acting Treatment & Prevention Options

REPRIEVE Trial Introduction

1 Cardiovascular Disease in People with HIV What the REPRIEVE Trial has Taught us Thus Far

REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

Clinical Education Initiative

Statin reduces fat deposits in arteries in people with HIV

HIV AIDS PREVENTION

The rise of virtual clinical trials

COMPLETE study results

Insights into the REVEAL trial: the efficacy of ruxolitinib for the treatment of patients with PV

VJHemOnc – Video Journal of Hematology & HemOnc

The ClinicalTrials.gov Results Database and Its Relationship to the Peer-Reviewed Literature

Peer Review Congress

Five-year Results From the IRONIC Trial

Radcliffe Cardiology

Elective Care Pathway Case Study: Dr Miten Ruparelia, Clinical Peer Review